Rein Therapeutics Inc
RNTX1.420USD
+0.130+10.08%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
35.70MMarket Cap
LossP/E TTM
More Details of Rein Therapeutics Inc Company
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Rein Therapeutics Inc Info
Ticker SymbolRNTX
Company nameRein Therapeutics Inc
IPO dateJun 29, 2017
CEOWindsor (Brian)
Number of employees11
Security typeOrdinary Share
Fiscal year-endJun 29
Address12407 N. Mopac Expy.
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78758
Phone17378021989
Websitehttps://www.reintx.com/
Ticker SymbolRNTX
IPO dateJun 29, 2017
CEOWindsor (Brian)
Company Executives of Rein Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Mr. Alan A. Musso, CPA
Mr. Alan A. Musso, CPA
Independent Director
Independent Director
--
--
Dr. Brian Windsor, Ph.D.
Dr. Brian Windsor, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Timothy M. (Tim) Cunningham, CPA
Mr. Timothy M. (Tim) Cunningham, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Manuel C. Alves Aivado, M.D., Ph.D.
Dr. Manuel C. Alves Aivado, M.D., Ph.D.
Director
Director
--
--
Dr. Reinhard J. Ambros, Ph.D.
Dr. Reinhard J. Ambros, Ph.D.
Independent Director
Independent Director
--
--
Mr. Josef H. Von Rickenbach
Mr. Josef H. Von Rickenbach
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Mr. Alan A. Musso, CPA
Mr. Alan A. Musso, CPA
Independent Director
Independent Director
--
--
Dr. Brian Windsor, Ph.D.
Dr. Brian Windsor, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Timothy M. (Tim) Cunningham, CPA
Mr. Timothy M. (Tim) Cunningham, CPA
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Manuel C. Alves Aivado, M.D., Ph.D.
Dr. Manuel C. Alves Aivado, M.D., Ph.D.
Director
Director
--
--
Dr. Reinhard J. Ambros, Ph.D.
Dr. Reinhard J. Ambros, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Voss Capital LLC
10.54%
Bios Equity Partners, LP.
6.43%
The Vanguard Group, Inc.
4.44%
Prosight Capital
2.16%
University of Texas Investment Management Company
1.95%
Other
74.48%
Shareholders
Shareholders
Proportion
Voss Capital LLC
10.54%
Bios Equity Partners, LP.
6.43%
The Vanguard Group, Inc.
4.44%
Prosight Capital
2.16%
University of Texas Investment Management Company
1.95%
Other
74.48%
Shareholder Types
Shareholders
Proportion
Hedge Fund
13.82%
Investment Advisor
6.77%
Venture Capital
6.49%
Investment Advisor/Hedge Fund
3.58%
Endowment Fund
1.95%
Research Firm
0.09%
Individual Investor
0.08%
Other
67.23%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
63
8.33M
34.38%
-387.31K
2025Q2
67
5.44M
23.61%
-2.73M
2025Q1
68
6.05M
27.36%
-2.07M
2024Q4
62
5.71M
26.36%
-2.11M
2024Q3
68
6.75M
31.73%
-1.30M
2024Q2
70
7.04M
33.12%
+1.08M
2024Q1
72
3.75M
76.83%
+1.75M
2023Q4
68
1.31M
26.94%
-611.73K
2023Q3
73
1.46M
32.12%
-497.50K
2023Q2
81
1.44M
31.62%
-549.81K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Voss Capital LLC
2.67M
11.44%
+1.23M
+85.99%
Sep 24, 2025
Bios Equity Partners, LP.
1.69M
7.25%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
884.11K
3.79%
+167.32K
+23.34%
Jun 30, 2025
Prosight Capital
427.92K
1.84%
-2.08K
-0.48%
Jun 30, 2025
University of Texas Investment Management Company
511.61K
2.2%
--
--
Jun 30, 2025
Cable Car Capital LLC
420.00K
1.8%
--
--
Jun 30, 2025
Sigma Planning Corporation
276.78K
1.19%
-28.40K
-9.31%
Jun 30, 2025
Geode Capital Management, L.L.C.
245.46K
1.05%
-641.00
-0.26%
Jun 30, 2025
Senvest Management, LLC
230.90K
0.99%
--
--
Jun 30, 2025
Gagnon Securities LLC
71.75K
0.31%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 10, 2022
Merger
20→1
Nov 10, 2022
Merger
20→1
Nov 10, 2022
Merger
20→1
Nov 10, 2022
Merger
20→1
Date
Type
Ratio
Nov 10, 2022
Merger
20→1
Nov 10, 2022
Merger
20→1
Nov 10, 2022
Merger
20→1
Nov 10, 2022
Merger
20→1
FAQs
Who are the top five shareholders of Rein Therapeutics Inc?
The top five shareholders of Rein Therapeutics Inc are:
Voss Capital LLC holds 2.67M shares, accounting for 11.44% of the total shares.
Bios Equity Partners, LP. holds 1.69M shares, accounting for 7.25% of the total shares.
The Vanguard Group, Inc. holds 884.11K shares, accounting for 3.79% of the total shares.
Prosight Capital holds 427.92K shares, accounting for 1.84% of the total shares.
University of Texas Investment Management Company holds 511.61K shares, accounting for 2.20% of the total shares.
Voss Capital LLC holds 2.67M shares, accounting for 11.44% of the total shares.
Bios Equity Partners, LP. holds 1.69M shares, accounting for 7.25% of the total shares.
The Vanguard Group, Inc. holds 884.11K shares, accounting for 3.79% of the total shares.
Prosight Capital holds 427.92K shares, accounting for 1.84% of the total shares.
University of Texas Investment Management Company holds 511.61K shares, accounting for 2.20% of the total shares.
What are the top three shareholder types of Rein Therapeutics Inc?
The top three shareholder types of Rein Therapeutics Inc are:
Voss Capital LLC
Bios Equity Partners, LP.
The Vanguard Group, Inc.
Voss Capital LLC
Bios Equity Partners, LP.
The Vanguard Group, Inc.
How many institutions hold shares of Rein Therapeutics Inc (RNTX)?
As of 2025Q3, 63 institutions hold shares of Rein Therapeutics Inc, with a combined market value of approximately 8.33M, accounting for 34.38% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 10.78%.
What is the biggest source of revenue for Rein Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Rein Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
